Opus Genetics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Für Opus Genetics wird ein Gewinn- und Umsatzwachstum von 55.2% bzw. 57.5% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 54.1% pro Jahr steigen soll.

Wichtige Informationen

55.2%

Wachstumsrate der Gewinne

54.13%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.2%
Wachstumsrate der Einnahmen	57.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	21 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Feb 07

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

Opus Genetics, Inc. ( NASDAQ:IRD ) shareholders have had their patience rewarded with a 43% share price jump in the...

Analyseartikel • Dec 11

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 27% in...

Analyseartikel • Sep 09

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 31% in...

Analyseartikel • Jul 11

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc.'s ( NASDAQ:IRD ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right now...

Analyseartikel • May 19

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

Investors in Opus Genetics, Inc. ( NASDAQ:IRD ) had a good week, as its shares rose 7.4% to close at US$1.02 following...

Analyseartikel • Apr 09

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Opus Genetics, Inc. ( NASDAQ:IRD ) share price has dived 25% in the last...

Analyseartikel • Aug 19

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Celebrations may be in order for Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders, with the analysts delivering a...

Analyseartikel • Jul 24

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders have had their patience rewarded with a 30% share price jump in the...

Analyseartikel • Jul 12

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyseartikel • May 02

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) share price has dived 26% in the last...

Analyseartikel • Mar 15

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders that were waiting for something to happen have been dealt a blow...

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:IRD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	30	-67	-24	N/A	10
12/31/2027	16	-67	-49	N/A	15
12/31/2026	16	-88	-46	N/A	16
3/31/2026	12	-107	N/A	N/A	N/A
12/31/2025	14	-50	-35	-35	N/A
9/30/2025	15	-68	-33	-33	N/A
6/30/2025	15	-58	-32	-32	N/A
3/31/2025	14	-59	-29	-29	N/A
12/31/2024	11	-58	-26	-26	N/A
9/30/2024	8	-27	-14	-14	N/A
6/30/2024	16	-14	-11	-11	N/A
3/31/2024	19	-11	-3	-3	N/A
12/31/2023	19	-10	-1	-1	N/A
9/30/2023	57	29	23	23	N/A
6/30/2023	45	19	22	22	N/A
3/31/2023	42	19	17	17	N/A
12/31/2022	40	18	14	14	N/A
9/30/2022	N/A	-22	-20	-20	N/A
6/30/2022	0	-22	-19	-19	N/A
3/31/2022	1	-24	-20	-20	N/A
12/31/2021	1	-57	-19	-19	N/A
9/30/2021	1	-69	-20	-18	N/A
6/30/2021	0	-66	-17	-16	N/A
3/31/2021	N/A	-61	-13	-12	N/A
12/31/2020	N/A	-25	-8	-7	N/A
9/30/2020	N/A	-8	-4	-4	N/A
6/30/2020	N/A	-9	-4	-4	N/A
3/31/2020	N/A	-8	-4	-4	N/A
12/31/2019	N/A	-6	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IRD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IRD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IRD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IRDDie Einnahmen des Unternehmens (57.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.8% pro Jahr).

Hohe Wachstumseinnahmen: IRDDie Einnahmen des Unternehmens (57.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IRD in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/26 20:52
Aktienkurs zum Tagesende	2026/05/26 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Opus Genetics, Inc. wird von 15 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 77%

Consensus EPS estimates fall by 19%, revenue upgraded

Price target increased by 7.5% to US$9.50

Price target increased by 14% to US$8.83

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to US$6.80

Recent updates

Consensus EPS estimates fall by 77%

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Opus Genetics Completes Enrollment In Cohort 1 Of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces Fda Acceptance of Opgx-Lca5 into Rare Disease Evidence Principles (Rdep) Program

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLC

High number of new directors

Consensus EPS estimates fall by 19%, revenue upgraded

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Price target increased by 7.5% to US$9.50

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 14% to US$8.83

Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

New minor risk - Share price stability

Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa

Independent Chairman recently bought US$324k worth of stock

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Consensus EPS estimates fall by 16%, revenue upgraded

Third quarter 2025 earnings: EPS misses analyst expectations

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Price target increased by 13% to US$6.80

New major risk - Revenue and earnings growth

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Consensus revenue estimates decrease by 18%, EPS upgraded

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

New major risk - Financial position

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Consensus revenue estimates increase by 16%

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67